Equities

Genomed SA

GEN:WSE

Genomed SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)29.60
  • Today's Change0.00 / 0.00%
  • Shares traded1.00
  • 1 Year change-26.00%
  • Beta--
Data delayed at least 15 minutes, as of Apr 24 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genomed SA is a Poland-based company engaged in genetic research. It develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The Company also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

  • Revenue in PLN (TTM)22.48m
  • Net income in PLN996.34k
  • Incorporated2010
  • Employees--
  • Location
    Genomed SAul. Ponczowa 12WARSZAWA 02-971PolandPOL
  • Phone+48 226446019
  • Fax+48 226446025
  • Websitehttp://www.genomed.pl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Private Rented Sector SA200.00k27.20k8.59m--315.69--91.6042.950.02060.02060.1514-0.0351.79--2.20--24.281,266.23----23.89-1,935.5513.602,755.44-------------66.26------
Inno-Gene SA1.13m-1.46m10.26m27.00--1.55--9.10-0.2559-0.25590.19791.160.10864.670.673---14.047.92-19.0710.7339.1873.63-129.3411.592.58--0.0362---93.08-16.73-542.12------
Sygnis SA15.75m-8.22m15.85m--------1.01-0.3614-0.36140.6925-------------6.10---9.5750.8256.46-53.74-22.44---10.62-----33.3844.26-266.18------
Braster SA1.31m-3.83m16.24m16.00------12.42-0.2825-0.28250.0561-0.17340.06010.0769163.38---17.61-29.23-220.50-50.2771.1668.77-293.04-1,435.540.3061-2.591.62--413.7641.3542.87------
Nanogroup SA-23.32k-1.82m20.30m----2.76-----0.06-0.06-0.00130.3655-0.001344.40-----9.95-17.12-12.41-19.06---276.06---1,180.741.09--0.0088---71.6627.8891.62---38.43--
Stem Cells Spin SA419.32k-154.01k20.67m----2.7822.1949.29-0.0037-0.00370.01010.17970.02940.07461.57---1.08-1.14-1.76-1.9389.3694.37-36.73-45.340.0363-124.050.0153--68.84-4.37-678.77---52.67--
Genxone SA2.39m-3.72m24.20m----1.62--10.10-1.13-1.130.72654.540.135813.395.04---21.0914.58-22.0416.46-23.1848.42-155.3120.4116.91--0.0039---77.38111.39-874.87---28.78--
Pure Biologics SA109.00k-31.72m25.55m53.00--1.96--234.42-11.15-11.150.03774.050.0023--0.10261,135.42-66.46-48.68-81.74-83.38-3,960.5538.81-29,097.25-195.73---11.410.7606--160.63-7.58-117.62------
Cannabis Poland SA199.93k-675.76k27.06m----49.68--135.36-0.0255-0.02550.00760.01110.30180.82645.07---102.76-116.92-175.94-136.3026.1612.29-340.53-959.391.35-45.880.2547---47.5550.2314.30------
GENOMED SA22.48m996.34k39.11m--39.253.8624.221.740.75410.754117.017.662.006.2913.81--8.877.9010.249.3342.8538.564.433.934.103,257.61----9.853.87193.38-7.69-32.19--
Inventionmed SA610.00-2.46m44.21m9.00--8.25--72,471.48-0.0121-0.01210.000.02640.00002--0.000467.78-7.00-18.09-11.73-23.28-1,288.53-48.77-403,196.70-43,186.79---2.11-----85.01--88.90------
Data as of Apr 24 2024. Currency figures normalised to Genomed SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.